DrugPatentWatch – Make Better Decisions's articles Biotechnology New patent for Vanda Pharms drug HETLIOZ LQ Annual Drug Patent Expirations for HETLIOZ+LQ Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in […] Source Source Written by DrugPatentWatch – Make Better Decisions January 22, 2025January 22, 2025 Saving Bookmark this article Bookmarked Biotechnology New patent for Arcutis drug ZORYVE Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for ZORYVE Zoryve is a drug marketed by Arcutis and is included in two NDAs. It is available from one supplier. There are seven patents protecting this drug. ZORYVE drug price trends. This drug has forty-two patent family members in twelve countries. The generic […] Written by DrugPatentWatch – Make Better Decisions January 5, 2025January 5, 2025 Saving Bookmark this article Bookmarked Biotechnology New patent for Vanda Pharms drug HETLIOZ Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […] Written by DrugPatentWatch – Make Better Decisions December 20, 2024December 20, 2024 Saving Bookmark this article Bookmarked Biotechnology Which pharmaceutical drugs have the most drug patents in United Kingdom? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in United Kingdom are: Onzetra Xsail Xhance Evzio Evzio (autoinjector) […] Written by DrugPatentWatch – Make Better Decisions November 23, 2024November 23, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions November 10, 2024November 10, 2024 Saving Bookmark this article Bookmarked Biotechnology Which pharmaceutical companies have the most SPCs in Ireland? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation bycompensating for the long time needed to obtain regulatory approval for drugs. SPCscome into force only after the corresponding general […] Written by DrugPatentWatch – Make Better Decisions October 27, 2024October 27, 2024 Saving Bookmark this article Bookmarked Biotechnology New patent expiration for United Therap drug ORENITRAM Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for ORENITRAM Orenitram is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for ORENITRAM. This drug has fifty-nine patent […] Written by DrugPatentWatch – Make Better Decisions October 14, 2024October 14, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […] Source Source Written by DrugPatentWatch – Make Better Decisions September 27, 2024September 27, 2024 Saving Bookmark this article Bookmarked Biotechnology Which pharmaceutical drugs have the most drug patents in Austria? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in Austria are: Adasuve Abilify Maintena Kit Vistogard Zetia Abilify Nucynta […] Written by DrugPatentWatch – Make Better Decisions September 10, 2024September 10, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions August 25, 2024August 25, 2024 Saving Bookmark this article Bookmarked Biotechnology New patent for Abbvie drug RINVOQ LQ Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for RINVOQ+LQ Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib […] Written by DrugPatentWatch – Make Better Decisions June 19, 2024June 19, 2024 Saving Bookmark this article Bookmarked Biotechnology New tentative approval for MSN drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions June 2, 2024June 2, 2024 Saving Bookmark this article Bookmarked Loading Load more
Biotechnology New patent for Vanda Pharms drug HETLIOZ LQ Annual Drug Patent Expirations for HETLIOZ+LQ Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in […] Source Source Written by DrugPatentWatch – Make Better Decisions January 22, 2025January 22, 2025 Saving Bookmark this article Bookmarked
Biotechnology New patent for Arcutis drug ZORYVE Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for ZORYVE Zoryve is a drug marketed by Arcutis and is included in two NDAs. It is available from one supplier. There are seven patents protecting this drug. ZORYVE drug price trends. This drug has forty-two patent family members in twelve countries. The generic […] Written by DrugPatentWatch – Make Better Decisions January 5, 2025January 5, 2025 Saving Bookmark this article Bookmarked
Biotechnology New patent for Vanda Pharms drug HETLIOZ Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for HETLIOZ. This drug has one […] Written by DrugPatentWatch – Make Better Decisions December 20, 2024December 20, 2024 Saving Bookmark this article Bookmarked
Biotechnology Which pharmaceutical drugs have the most drug patents in United Kingdom? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in United Kingdom are: Onzetra Xsail Xhance Evzio Evzio (autoinjector) […] Written by DrugPatentWatch – Make Better Decisions November 23, 2024November 23, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions November 10, 2024November 10, 2024 Saving Bookmark this article Bookmarked
Biotechnology Which pharmaceutical companies have the most SPCs in Ireland? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation bycompensating for the long time needed to obtain regulatory approval for drugs. SPCscome into force only after the corresponding general […] Written by DrugPatentWatch – Make Better Decisions October 27, 2024October 27, 2024 Saving Bookmark this article Bookmarked
Biotechnology New patent expiration for United Therap drug ORENITRAM Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for ORENITRAM Orenitram is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and two Paragraph IV challenges. Drug patent litigation for ORENITRAM. This drug has fifty-nine patent […] Written by DrugPatentWatch – Make Better Decisions October 14, 2024October 14, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […] Source Source Written by DrugPatentWatch – Make Better Decisions September 27, 2024September 27, 2024 Saving Bookmark this article Bookmarked
Biotechnology Which pharmaceutical drugs have the most drug patents in Austria? Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. The companies with the greatest patent coverage in Austria are: Adasuve Abilify Maintena Kit Vistogard Zetia Abilify Nucynta […] Written by DrugPatentWatch – Make Better Decisions September 10, 2024September 10, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for Alembic drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions August 25, 2024August 25, 2024 Saving Bookmark this article Bookmarked
Biotechnology New patent for Abbvie drug RINVOQ LQ Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for RINVOQ+LQ Rinvoq Lq is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. The generic ingredient in RINVOQ LQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib […] Written by DrugPatentWatch – Make Better Decisions June 19, 2024June 19, 2024 Saving Bookmark this article Bookmarked
Biotechnology New tentative approval for MSN drug dabigatran etexilate mesylate Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are […] Written by DrugPatentWatch – Make Better Decisions June 2, 2024June 2, 2024 Saving Bookmark this article Bookmarked
